Effect of a cheese rich in angiotensin-converting enzyme-inhibiting peptides (Gamalost®) and a Gouda-type cheese on blood pressure: Results of a randomised trial

Food and Nutrition Research

Volumn 60, Issue , 2016, Pages

  Nilsen, Rita ^a   Pripp, Are H ^b   Høstmark, Arne T ^c   Haug, Anna ^a   Skeie, Siv ^a  

^a NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Bioactive peptides; Cardiovascular diseases; Dairy; Gamalost; Gouda; Intervention

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME INHIBITING PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHEESE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DIETARY HABIT; FEMALE; GAMALOST; GOUDA; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUTRITIONAL ASSESSMENT; NUTRITIONAL PARAMETERS; OUTCOME ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84990879582     PISSN: 16546628     EISSN: None     Source Type: Journal    
DOI: 10.3402/fnr.v60.32017     Document Type: Article

References (38)

1. Alwan A. Global status report on noncommunicable diseases 2010. World Health Organization; 2011. Available from: http://www.who.int/nmh/publications/ncd-report-full-en.pdf [cited 4 April 2015].
2. World Health Organization. The top 10 causes of death. 2014. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/ [cited 22 August 2014].
3. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335(8692): 765-74.
4. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-60. doi: http://dx.doi.org/10.1016/S0140-6736(12)61766-8
5. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47(2): 296-308.
6. Sacks FM, Svetkey S, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344(1): 3-10. doi: http://dx.doi.org/10.1056/NEJM200101043440101
7. He J, Wofford MR, Reynolds K, Chen J, Chen CS, Myers L, et al. Effect of dietary protein supplementation on blood pressure: a randomised, controlled trial. Circulation 2011; 124(5): 589-95.
8. Wang L, Manson JE, Buring JE, Lee IM, Sesso HD. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008; 51(4): 1073-9. doi: http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.107821
9. Houston M. The importance of potassium in managing hypertension. Curr Hypertens Rep 2011; 13: 309-17.
10. Korhonen H, Pihlanto A. Bioactive peptides: production and functionality. Int Dairy J 2006; 16: 945-60.
11. Silva SV, Malcata FX. Caseins as source of bioactive peptides. Int Dairy J 2005; 15: 1-15.
12. Pritchard SR, Phillips M, Kailasapathy K. Identification of bioactive peptides in commercial Cheddar cheese. Food Res Int 2010; 43: 1545-8.
13. Gomez-Ruiz JA, Ramos M, Recio I. Angiotensin-converting enzyme-inhibitory peptides in Manchego cheeses manufactured with different starter cultures. Int Dairy J 2002; 12: 697-706.
14. Lignitto L, Cavatorta V, Balzan S, Gabai G, Galaverna G, Novelli E, et al. Angiotensin-converting, enzyme inhibitory activity of water-soluble extracts of Asiago d'allevo cheese. Int Dairy J 2010; 20(1): 11-17.
15. Qureshi TM, Vegarud GE, Abrahamsen RK, Skeie S. Characterization of the Norwegian autochthonous cheese Gamalost and its angiotensin I-converting enzyme (ACE) inhibitory activity during ripening. Dairy Sci Technol 2012; 92(6): 613-25. doi: http://dx.doi.org/10.1007/s13594-012-0078-1
16. Pripp A. Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomised controlled trials. Food Nutr Res 2008; 52. doi: 10.3402/fnr.v52i0.1641
17. Pripp AH, Sorensen R, Stepamak L, Sorhaug T. Relationship between proteolysis and angiotensin-I-converting enzyme inhibition in different cheeses. LWT Food Sci Technol 2006; 39(6): 677-83. doi: http://dx.doi.org/10.1016/j.lwt.2005.03.018
18. Qureshi TM, Vegarud GE, Abrahamsen RK, Skeie S. Angiotensin 1-converting enzyme (ACE) inhibitory activity of the Norwegian autochthonous cheese Gamalost and Norvegia after in vitro human gastrointestinal digestion. J Dairy Sci 2013; 96(2): 838-53. doi: http://dx.doi.org/10.3168/jds.2012-5993
19. Sieber R, Butikofer U, Egger C, Portmann R, Walther B, Wechsler D. ACE-inhibitory activity and ACE-inhibiting peptides in different cheese varieties. Dairy Sci Technol 2010; 90(1): 47-73. doi: http://dx.doi.org/10.1051/dst/2009049
20. Nilsen R, Pripp AH, Høstmark AT, Haug A, Skeie S. Short communication: is consumption of a cheese rich in angiotensin-converting enzyme-inhibiting peptides, such as the Norwegian cheese Gamalost, associated with reduced blood pressure? J Dairy Sci 2014; 97(5): 2662-8. doi: http://dx.doi.org/10.3168/jds.2013-7479
21. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Hypertension 2005; 45(1): 142-61. doi: http://dx.doi.org/10.1161/01.HYP.0000150859.47929.8e
22. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press 2014; 23(1): 3-16.
23. WHO (2011). Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. Geneva, Switzerland: WHO.
24. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215-20.
25. Modesti PA. Season, temperature and blood pressure: a complex interaction. Eur J Intern Med 2013; 24(7): 604-7.
26. Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D, Salas-Salvado J, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomised controlled trial. BMC Med 2013; 11: 207.
27. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155(7): 701-9.
28. Engberink MF, Schouten EG, Kok FJ, van Mierlo LAJ, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure. Hypertension 2008; 51(2): 399-405. doi: http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.098988
29. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 2005; 24(4): 257-65.
30. Karlsen A, Svendsen M, Seljeflot I, Laake P, Duttaroy AK, Drevon CA, et al. Kiwifruit decreases blood pressure and whole-blood platelet aggregation in male smokers. J Hum Hypertens 2013; 27(2): 126-30.
31. Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension 2013; 62(6): 1081-9.
32. Conway V, Couture P, Gauthier S, Pouliot Y, Lamarche B. Effect of buttermilk consumption on blood pressure in moderately hypercholesterolemic men and women. Nutrition 2014; 30(1): 116-19.
33. Katz DL, Davidhi A, Ma Y, Kavak Y, Bifulco L, Njike VY. Effects of walnuts on endothelial function in overweight adults with visceral obesity: a randomised, controlled, crossover trial. J Am Coll Nutr 2012; 31(6): 415-23.
34. Sumner DJ, Meredith PA, Howie CA, Elliott HL. Initial blood pressure as predictor of the response to antihypertensive therapy. Br J Clin Pharmacol 1988; 26(6): 715-20.
35. Fekete AA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients 2015; 7: 659-81.
36. Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-coat hypertension new insights from recent studies. Hypertension 2013; 62(6): 982-7.
37. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood pressure monitoring. Task force V: white-coat hypertension. Blood Press Monit 1999; 4(6): 333-41.
38. O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31(9): 1731-68.